Biotech & Life SupportThe Human Hardware
Amgen
AMGNHOLDPublic · USA
Biotechnology medicines for serious illnesses including oncology and cardiovascular disease Visit website
$460.73
▲ +2.0% as of Oct 29
CONVICTION SCORE
41
Mixed
Execution Velocity
Score computed, inputs as of Oct 2026 · signal and velocity are editorial
WHY THIS SCORE
MethodologyExecution3840%
- Wins in the Feed: not measured: no sourced item about this company in the Feed in 90 days
- Orbital launches: not applicable: not an orbital launch provider that has flown
- Revenue growth: 38, +9% a year, trailing twelve months (lower than the quarter)
Milestones3025%
- Ladder 0: not a named contributor to any rung on the Dew Point ladder
- Own timelines 60: execution velocity Mixed, editorial and ledgered
Signals4420%
- Feed: nothing sourced in 90 days (neutral)
- Form 4: 0 open-market purchases, 2 sales outside a 10b5-1 plan, in 90 days (-6)
Coverage6015%
- Breadth 50: 1 sector
- Scarcity 75: Biotech & Life Support has 4 covered names
0.40 × 38 + 0.25 × 30 + 0.20 × 44 + 0.15 × 60 = 40.6 → 41
No editorial adjustment. A reviewer may move a computed score by up to 10 points with a reason, recorded on the scorecard.
Inputs frozen Oct 23, 2026 from the site's own feeds: the Feed and Form 4 over 90 days, launches over 365 days, revenue over the trailing year. Next review by Jan 21, 2027. The share price and analyst ratings are not inputs.
DETAILS
Cap Tier
Mega
Civ Phase
Orbital & Lunar
SECTORS
Biotech & Life Support ★
PEERS
Biotech & Life SupportScore, then day change (live quotes). Nearest by sector, then by score.
The Morning Dew, in your inbox
The daily brief, live quotes and the newest signals, every morning. Plus a Friday recap of the week. Nothing else, ever.